Products
FOXO3A antibody
- Product Name
- FOXO3A antibody
- Catalogue No.
- FNab10245
- Size
- 100μg
- Form
- liquid
- Purification
- Immunogen affinity purified
- Purity
- ≥95% as determined by SDS-PAGE
- Clonality
- polyclonal
- Isotype
- IgG
- Storage
- PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20℃ for 12 months (Avoid repeated freeze / thaw cycles.)
Immunogen
- Immunogen
- forkhead box O3
- Alternative Names
- AF6q21 antibody, AF6q21 protein antibody, DKFZp781A0677 antibody, FKHRL1 antibody, FKHRL1P2 antibody, forkhead box O3 antibody, Forkhead box protein O3 antibody, FOXO2 antibody, FOXO3 antibody, FOXO3A antibody
- UniProt ID
- O43524
- Observed MW
- 90 kDa
Application
- Tested Applications
- ELISA, WB, IHC
- Recommended dilution
- WB: 1:500 - 1:2000; IHC: 1:50 - 1:200
Validated Images
HEK-293 cells were subjected to SDS PAGE followed by western blot with FNab10245(FOXO3A antibody) at dilution of 1:1000
Immunohistochemistry of paraffin-embedded human breast cancer using FNab10245(FOXO3A antibody) at dilution of 1:50
- Background
- Forkhead box O-class (FOXO) transcription factors are mammalian homologue of DAF-16, a known lifespan regulator of Caenorhabditis elegans. FOXO transcription factors, such as FOXO1, FOXO3a, and FOXO4, have been linked to the regulation of cell cycle, apoptosis, DNA repair, oxidative stress, and metabolism. FOXO proteins are proposed to be dual regulated by Akt-mediated phosphorylation and Skp2-mediated ubiquitination, which are usually initiated by growth factors and cytokines. FOXO proteins are also activated by stress, which induces gene expression that contributes to cell cycle arrest, implicating FOXO proteins as tumor suppressors. Specifically, FOXO3a (FKHR-L1) is a transcriptional activator for apoptosis in the absence of survival factors, such as in neural cell death triggered by oxidative stress. In the presence of survival factors like IGF-1, AKT1/PKB phosphorylates on Thr-32 and Ser-253. FOXO3a is inactivated when phosphorylated by AKT1 on Thr-32 and Ser-253.
